Rosuvastatin calcium in acute coronary syndromes

@article{Aggarwal2013RosuvastatinCI,
  title={Rosuvastatin calcium in acute coronary syndromes},
  author={R. Aggarwal and R. Showkathali},
  journal={Expert Opinion on Pharmacotherapy},
  year={2013},
  volume={14},
  pages={1215 - 1227}
}
  • R. Aggarwal, R. Showkathali
  • Published 2013
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Introduction: Low-density lipoprotein cholesterol (LDL-C) reduction using 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) has a proven survival benefit in patients presenting with acute coronary syndromes (ACS). Patients presenting with ACS remain at significant risk of subsequent cardiovascular death and non-fatal myocardial infarction despite high compliance with current guideline indicated secondary prevention therapies. There remains, therefore, a need to… CONTINUE READING
    13 Citations
    Review on Rosuvastatin
    Rosuvastatin protects against oxidized low-density lipoprotein-induced endothelial cell injury of atherosclerosis in vitro
    • 5
    • PDF
    Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
    • 3
    • PDF

    References

    SHOWING 1-10 OF 96 REFERENCES
    Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
    • L. Lopez
    • Medicine
    • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
    • 2002
    • 9
    • PDF
    The evolving role of statins in the management of atherosclerosis.
    • 565
    • PDF
    Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
    • 68
    • PDF
    Rosuvastatin: efficacy, safety and clinical effectiveness.
    • 26
    Early statin initiation and outcomes in patients with acute coronary syndromes.
    • 70
    • PDF
    Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    • 41
    • Highly Influential
    Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy
    • R. Rosenson
    • Medicine
    • American journal of cardiovascular drugs : drugs, devices, and other interventions
    • 2001
    • 61
    Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
    • M. Davidson
    • Medicine
    • Expert opinion on investigational drugs
    • 2002
    • 28
    Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    • 174
    • PDF
    Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    • 1,820
    • PDF